Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
287 participants
OBSERVATIONAL
2015-11-08
2019-09-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
observation of salivary IL-6 levels
Observation of salivary IL-6 levels
Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
Periodontitis
observation of salivary IL-6 levels
Observation of salivary IL-6 levels
Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation of salivary IL-6 levels
Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CP with a minimum of 40% of sites with a clinical attachment level (CAL)
≥2mm and probing depth (PD) ≥4mm;
* Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
* Presence of ≥40% sites with bleeding on probing (BOP)
Exclusion Criteria
* Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
* Status of pregnancy or lactation
* Previous history of excessive drinking
* Allergy to local anaesthetic
* Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.
35 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Messina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gaetano Isola, DDS, PhD
Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giovanni Matarese
Role: STUDY_CHAIR
University of Messina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Messina
Messina, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-1818
Identifier Type: -
Identifier Source: org_study_id